Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

124 results about "Plasmodium sp" patented technology

Plasmodium spp. is a genus of protozoal (single-celled) parasites that are usually transmitted by mosquitoes and belong to the Plasmodiidae family. Four species of plasmodium infect humans (P. vivax, P. ovale, P. malariae, P. falciparum) and trigger different forms of malaria.

Polymeric Compounds And Methods Of Making And Using The Same

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin / low molecular weight heparin derivative.
Owner:CELLCEUTIX CORP

Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and protozoan nucleic acids

Herein disclosed are rapid real-time isothermal multiplex methods of detecting, identifying and quantifying bacterial, viral, and protozoan nucleic acids in a sample. These include contacting the sample with two or more sets of pathogen-specific reverse transcription loop-mediated isothermal amplification primers and novel oligofluorophores specific for the target bacterial, viral, and parasitic nucleic acids of interest such as human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania, Trypanosoma, and Zika virus nucleic acids, under conditions sufficient to produce detectable real-time amplification signals in about 10 to 40 minutes. The amplification signals are produced by pathogen-specific fluorogenic labels included in one or more of the primers. Also, novel reaction and sample lysis buffers, primers, and kits for rapid multiplex detection, quantification, and identification of bacterial, viral, and protozoan nucleic acids by real-time isothermal amplification are herein disclosed.
Owner:NYAN DOUGBEH CHRIS

Inhibitors of the plasmodial surface anion channel as antimalarials

Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
Owner:UNITED STATES OF AMERICA

Multiple polymerase chain reaction (PCR) kit and method for detecting mosquito-borne pathogens

The invention provides a multiple polymerase chain reaction (PCR) kit for detecting mosquito-borne pathogens. The kit comprises six pairs of specific primers. The invention also provides a method for detecting the mosquito-borne pathogens. Electrophoresis is performed on a PCR-amplified product. Whether pathogens, such as encephalitis B virus, dengue fever virus, yellow fever virus, plasmodium falciparum, plasmodium vivax, plasmodium knowlesi, plasmodium ovale, plasmodium malariae, wuchereria malayi, wuchereria bancrofti and the like, exists or not is detected and identified according to the length of a PCR-amplified fragment. By the method, various reported mosquito-borne pathogens, and the yellow fever virus and west nile virus which come from other countries can be detected quickly, accurately and sensitively at the same time, and can be applied to the detection of various samples, such as mosquitoes, blood of patients, tissue fluid and the like. The invention provides a low-cost and high-efficient method for early monitoring and finding mosquito-borne disease prevalence for prevention and control work of mosquito-borne diseases in China.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Primers, probes and method for detecting plasmodium

The invention discloses primers, probes and a method for detecting plasmodium, belonging to the technical fields of biological detection and biological chemistry. The adopted technical scheme is as follows: the invention provides a method for detecting plasmodium, universal primers SEQ ID No: 1-2 for PCR (Polymerase Chain Reaction) amplification of gene sequences of plasmodium in the method, and probes SEQ ID No: 3-6 for detecting plasmodium. The primers, probes and method have the advantages that (1) the universal primers for PCR amplification of the gene sequences of plasmodium and the specific nucleic acid probes are high in sensitivity and good in accuracy; (2) due to the adoption of an asymmetric PCR method and liquid chip combined technology, the yield of a single strand of a biological marker is increased so that the hybridization and combination efficiencies of PCR products and microspheres coupled with the specific nucleic acid probes are increased; the method has the advantages of high-flux test, high specificity and sensitivity, stable result, good repeatability, simplicity in operation, high detection speed and capability of rapidly detecting plasmodium.
Owner:河北国际旅行卫生保健中心

Preparation and usage of plasmodium fusion antigen

The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1 / MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer

A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
Owner:GENEXINE INC

Preparation and application of hemorrhagic fever associated pathogen identifying gene chip

The invention relates to a hemorrhagic fever associated pathogen identifying gene chip; the preparation method comprises preparation of a specific primer, preparation of a pathogen specific oligonucleotide probe, preparation of an oligonucleotide chip, establishment of an RT-PCR (reverse transcription-polymerase chain reaction) system and establishment of a hybrid system and a signal detection method. The gene chip prepared by the invention can be used for simultaneously identifying 16 hemorrhagic fever associated pathogen microorganisms, including Zaire Ebola virus, Sudan Ebola virus, marburg virus, lassa virus, junin virus, Machupo virus, rift valley fever virus, Crimea-Congo hemorrhagic fever virus, plasmodium, hantaan virus, SFTS (severe fever with thrombocytopenia syndrome) virus, dengue virus, yellow fever virus, Chikungunya virus, influenza A virus and influenza B virus. The gene chip has the characteristics of being rapid and accurate, high in throughput and high in sensitivity; and a new technological means is offered for the diagnosis of hemorrhagic fever pathogen, health supervision and the control and prevention of infectious diseases.
Owner:ZHEJIANG CENT FOR DISEASE CONTROL & PREVENTION +1

Antibody against lactate dehydrogenase of plasmodium vivax, related preparation method, hybridoma cell strain and application

The invention provides an antibody against lactate dehydrogenase of plasmodium vivax, which is a monoclonal antibody or polyclonal antibody specific to proteins shown in SEQ ID NO: 2. More preferably, the monoclonal antibody or polyclonal antibody is obtained by using a fusion protein formed by the protein shown in SEQ ID NO: 2 and the known label as an antigen immune animal; the monoclonal antibody is produced by a hybridoma cell strain of which the collection number is CGMCC No.3897 or No.3898. The invention also provides a hybridoma cell strain producing the antibody against the lactate dehydrogenase of plasmodium vivax, a preparation method and use of the antibody against the lactate dehydrogenase of plasmodium vivax, a related immunoassay method, a kit prepared from the antibody, etc. The antibody against the lactate dehydrogenase of plasmodium vivax can specifically detect the lactate dehydrogenase of plasmodium vivax, can be applied to specificity detection of vivax infection, has the advantages of high specificity, sensitive response and low cost, and is applicable to high-throughput detection.
Owner:SHANGHAI MUNICIPAL CENT FOR DISEASE CONTROL & PREVENTION

High-flux rapid malaria serum detection method based on micro-fluidic chip

The invention belongs to the fields of biomedical research and clinical applications, and relates to a serum immunological detection method. According to the invention, based on a micro-fluidic chip, a method specially used for high-flux rapid malaria serum detection is established. With the method provided by the invention, immunological determinations of two plasmodium antigens are simultaneously carried out on a micro-fluidic chip. Analysis capacity and antigen-antibody reaction specificity of the micro-fluidic chip are combined, such that defects of conventional immunoassay can be effectively overcome, reaction efficiency can be improved, operation steps can be simplified, detection time can be shortened, patient serum sample usage amount can be greatly reduced, and consumptions of reagents and energy are greatly reduced. Thereby, the entire detection cost is reduced. Also, the method is advantaged in high automation degree. With the method, specimen room contamination can be prevented, and detection accuracy can be improved.
Owner:FUDAN UNIV

Amide derivative and purpose thereof

InactiveCN101565418AOrganic active ingredientsOrganic chemistryFuranEnzyme level
The invention relates to an amide derivative and a purpose thereof. The invention discloses an N-(4-substiguted aminoacyl phenyl)-5-substited furan-2-formamide compound and tests the activity of the compound for inhibiting falcipain-2 in experiment of enzyme level in vitro, and the result indicates that the compound has strong inhibitory activity to falcipain- 2. Therefore, the N-(4-substiguted aminoacyl phenyl)-5-substited furan-2-formamide compound provided in the invention can act as cysteine protease (falcipain-2) inhibitor in food vacuole of plasmodium to stop further proliferation of plasmodium in a host.
Owner:EAST CHINA UNIV OF SCI & TECH +1

Preparation method of plasmodium vivax aldolase protein monoclonal antibody

The invention discloses a preparation of method of a plasmodium vivax aldolase protein monoclonal antibody. According to the antibody, aldolase protein is specifically used as targeting antigen; three dominant antigen epitopes A, B and C are selected and connected by flexible segments so as to form a recombinant D; enzyme cutting sites of BamHI and XhoI restriction enzymes are added on the upper course and the lower course of the recombinant, respectively; then the product after double enzyme cutting processes is inserted into PET-28a (+) carrier so as to structure a recombined protein D expression carrier; the recombined protein D is expressed by escherichia coli BL21; a Balb / c mouse is immunized; spleen cells of the mouse are taken and fused with sp2 / 0 myeloma cells; and finally ten hybridoma cell lines capable of stably secreting aldolase protein monoclonal antibody are obtained after filtering. The monoclonal antibody obtained by the method provided by the invention is capable of specifically identifying tertian plasmodium aldolase protein so that the monoclonal antibody is beneficial for the specific detection of tertian plasmodium infection; in addition, the specificity is high, the response is sensitive, and the experiment cost is low, so that the antibody is suitable for the high-pass rapid detection.
Owner:HANGZHOU ALLTEST BIOTECH

Malaria serum with anti-tumor function and preparation method and application of malaria serum with anti-tumor function

InactiveCN105748515AObvious apoptosisIncreased apoptotic rateMammal material medical ingredientsAntineoplastic agentsPlasmodium traguliMalaria
The invention discloses a malaria serum with an anti-tumor function and a preparation method and application of the malaria serum with the anti-tumor function.According to long-term arduous scientific experiments, the serum of patients with malaria has a certain anti-tumor function, and particularly the serum of patients with a syndrome of malaria and thrombocytopenia is effective in treatment or prevention of tumors, especially liver cancers, under specific concentration conditions.According to experiments, the serum has an evident apoptosis induction function on hepatoma cell strains (7721) cultured in vitro, and the hepatoma cell apoptosis induction ratio is increased along with increase of serum concentration.The malaria serum with the anti-tumor function and the preparation method and application of the malaria serum with the anti-tumor function provide theoretical and experimental bases for further researches on tumor cell apoptosis induction factors generated by plasmodia, breaks a new path for rediscovery pathogenesis of critical and cerebral malaria cases and epidemiologic researches of various plasmodium species and strains, and make new effort in application of the malaria serum or preparations thereof to preparation of medicines for treatment or prevention of the tumors, thereby having great scientific research values and significances.
Owner:GUANGXI ZHUANG AUTONOMOUS REGION CENT FOR DISEASE CONTROL & PREVENTION

Controllable genome-modified plasmodium, recombinant expression vector and construction method and application of controllable genome-modified plasmodium and recombinant expression vector

The invention relates to a controllable genome-modified plasmodium, a recombinant expression vector and the construction method and application of the controllable genome-modified plasmodium and the recombinant expression vector. The recombinant expression vector comprises a gene targeting long homologous arm, a gene targeting short homologous arm, a tetracycline repression protein gene expression cassette, a pyrimethamine resistance gene expression cassette and a target gene expression cassette, wherein the tetracycline repression protein gene expression cassette, the pyrimethamine resistance gene expression cassette and the target gene expression cassette are located between the gene targeting long homologous arm and the gene targeting short homologous arm, and tetracycline operator gene sequences are inserted in multiple transcriptional start sites of a target gene promoter, so that the recombinant expression vector can be used for conditional research of the functions of a certain functional gene in a plasmodium genome. Furthermore, a functional gene expression sequence, corresponding to a target gene, in the plasmodium genome is knocked out by means of the gene knockout technique; meanwhile, the recombinant expression vector is transfected into a plasmodium with genes knocked out, so that the controllable genome-modified plasmodium is obtained; a new technical scheme is provided for further research of the functions of all functional genes in the plasmodium genome, and application prospects are broad.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Reagent combination and kit for detecting blood transfusion transmitted pathogens and application

The invention discloses application of a reagent combination for detecting pathogens in preparation of a kit for detecting the quality of a blood product. The pathogens are selected from a pathogen group consisting of HAV, HBV, HCV, HEV, TP, HIV1, HIV2, HTLV1, HTLV2, HBOV, TTV, HCMV, B19, DENV, ZIKV, WNV, babesia, trypanosoma krusei and plasmodium, and belongs to the field of medical examination.The invention further discloses a corresponding kit and a method for detecting the quality of the blood product. By means of the kit, the lowest detection limit of pathogens is 1.0 * 10 < 3 > copies / mL, the kit has good specificity and repeatability, and an important technology is provided for screening and evaluating blood transfusion transmitted pathogens.
Owner:山西国际旅行卫生保健中心

Placental chondroitin sulfate A based cancer screening and early stage diagnosis reagent and method

The invention relates to a placental chondroitin sulfate A based cancer screening and early stage diagnosis reagent, and a method, and more specifically discloses an ELISA kit used for tumor detection. The ELISA kit comprises a capturing protein combined with placental chondroitin sulfate A (pl-CSA), and the capturing protein is preferably selected from the minimum bonding peptide segments of plasmodium infected erythrocyte surface antigen (VAR2CSA, rVAR2), and more preferably, the sequence of the minimum bonding peptide segment is represented by SEQ ID No.1. It is found for the first time that pl-CSA can be detected in a plurality of kinds of body fluid, so that basis is provided for in vitro qualitative or quantitative biological detection of pl-CSA. The method is low in detection limit,excellent in repeatability, and high in specificity.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Plasmodium malariae and plasmodium ovale genes and uses thereof

ActiveUS20090226445A1ProtozoaBiomass after-treatmentMerozoite surface proteinNucleic acid sequencing
The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.
Owner:ABBOTT LAB INC

Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens

The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic agent preferably comprises CpG nucleic acid, IL-12 protein and / or IL-12 nucleic acid. The pathogen is preferably an intracellular pathogen comprising one or more species and strains, such as Plasmodium spp. The invention also relates to a pharmaceutical composition comprising the immunogenic agent. The pharmaceutical composition is preferably an immunotherapeutic composition. The immunotherapeutic composition, is preferably a vaccine capable of providing protection against or treating Plasmodium spp infection, the causative agent of malaria in humans.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES +1

Novel uses of plasmodium circumsporozoite protein in resisting proliferation and migration of tumor

The invention discloses a new application of plasmodium circumsporozoite protein CSP for preparing medicaments for anti-tumor multiplication and migration. The invention successfully constructs a recombinant expression carrier pFLAG-CMV8-CSP of the CSP and transfects the recombinant expression carrier into a human liver cancer cell strain HepG2 and a colorectal cancer cell strain SW480 in a manner of liposome transfection. The research result shows that the CSP is mainly expressed in the cytoplasm of HepG2 cells, can restrain TNF-Alpha and LPS, stimulate the HepG2 cells and SW480 cells to activate NF-Kappa B and restrain the multiplication of the SW480 cells, and is further developed into a novel protein medicament for the anti-tumor multiplication and migration hopefully; and the recombinant expression carrier containing the gene of the CSP is hopefully further developed into the novel protein medicament for the anti-tumor multiplication and migration, therefore, the invention has favorable clinical application prospect.
Owner:ARMY MEDICAL UNIV

Preparation and usage of plasmodium fusion antigen

The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1 / MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Gene editing system based on CRISPR-Cas9 technology and application of gene editing system

The invention provides a gene editing system based on a CRISPR-Cas9 technology and application of the gene editing system. Based on an endogenous U6 promoter dependent-form vector system, a negative selection marker is added into a Cas9 expression box of an expression vector, an anti-drug selection marker on a rescue vector containing a homologous arm is transferred onto the expression vector, thus the base size of the rescue vector is decreased, and the capacity of the rescue vector is increased; and an exogenous gene segment lengthening out to 6.3 kb can be input in human plasmodium in a mediated mode, obtained recombinant plasmodium does not contain the anti-drug selection marker and Cas9 protein expression plasmid residue, continuous gene editing can be conducted through the same drugselection marker, and the gene editing system is stable in performance, efficient, concise, and powerful in function, and has wide application prospects and huge market value.
Owner:BLUE ELEGANT BIOTECH CO LTD

Recombinant vector, recombinant baculovirus prepared with the same and application of virus in preparation of malaria vaccines

The invention provides a recombinant vector, a recombinant baculovirus prepared with the vector and application of the virus in preparation of malaria vaccines. The recombinant vector is constructed by inserting a section of recombinant sequence into the pFastBacDual vector. The recombinant sequence is formed by: according to CMV, Ph, SP and TM sequences, adding EcoR I enzyme site and Xho I enzyme site between SP and TM, adding KpnI enzyme site in front of CMV-F, and adding HindIII enzyme site after TM-R. The recombinant baculovirus is obtained by: inserting Plasmodium yoelii Pys25 antigen gene into the recombinant vector, conducting homologous recombination with the genome of a shuttle vector Bacmid through transposition, then transfecting a bombyx mori cell, and performing packaging in the bombyx mori cell. Through simple separation and purification of the recombinant baculovirus, an antibody with good titer can be prepared, thus providing a reference for study of P25 malaria vaccines.
Owner:特菲(天津)生物医药科技有限公司

Compositions and methods for generating an immune response to treat or prevent malaria

The compositions and methods are described for generating an immune response to a Plasmodium antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to malaria by expressing the Plasmodium antigen in the subject to which the MVA vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and / or treat malaria.
Owner:GEOVAX INC

Method for detecting and identifying plasmodium sperozoites in mosquito medium

The invention discloses a method for detecting and identifying plasmodium sperozoites in a mosquito medium. The method comprises the following steps of: 1) designing a pair of primers; 2) extracting a plasmodium sperozoite genome deoxyribonucleic acid (DNA) in anopheles serving as a medium; 3) performing amplification on the plasmodium sperozoite genome DNA in the mosquito medium by a fluorescent quantitative polymerase chain reaction (PCR); and 4) melting an amplification product to obtain a melting curve, and comparing with positive control and negative control. The method has the advantages that: through the method for detecting and identifying plasmodium sperozoites in the mosquito medium and application thereof, plasmodia in the mosquito medium can be quantitatively detected, and can be qualitatively identified according to plasmid DNA standard substances of four constructed human plasmodia (which are shown as the figure 2), the sensibility and specificity of the detection and identification technology are improved, and compared with the prior art, the method is simple, convenient and quick and low in cost, and is suitable for evaluating the malaria control effect and monitoring malaria.
Owner:JIANGSU INST OF PARASITIC DISEASES

Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors

InactiveUS20110003764A1Improve abilitiesReinforce antiretroviral activityBiocideAntiviralsHydroxychloroquineImmunodeficiency virus
The present invention relates to a drug combination capable of conferring therapeutic benefits in the treatment of both AIDS and malaria. In particular, it relates to a drug combination including at least one quinolinic antimalarial compound such as chloroquine or hydroxychloroquine, and at least one inhibitor of the Human Immunodeficiency Virus (HIV) protease enzyme. This drug combination is capable of inhibiting the replication of both HIV and Plasmodium sp. It also relates to the direct antimalarial effects of the HIV PIs.
Owner:SAVARINO ANDREA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products